Low-dose CT for lung cancer screening among Veterans Health Administration patients will require substantial clinical effort.
CT lung cancer screening of U.S. Veteran Affairs patients will increase demand, resulting in substantial clinical effort for both patients and staff, according to a study published in JAMA Internal Medicine.
Researchers from North Carolina, Minnesota, Oregon, South Carolina, and Pennsylvania sought to estimate the number of Veterans Health Administration (VHA) patients who may be candidates for annual lung cancer screening (LCS) with low-dose computed tomography (LDCT). The project was conducted at eight academic VHA hospitals among 93,033 primary care patients who were assessed on screening criteria between July 1, 2013, and June 30, 2015. The researchers measured the percentages of patients who agreed to undergo LCS, had positive findings on results of LDCT, were found to have lung cancer, or had incidental findings; and the estimated number of VHA patients who met the criteria for LCS.
The results showed that 4,246 patients met the criteria for LCS; 2,452 (57.7%) agreed to undergo screening and 2,106 (2028 men and 78 women; mean age, 64.9) underwent LCS. Of the 2,106 patients screened, 1,257 (59.7%) had nodules. Among these patients:
• 1,184 (56.2%) required tracking
• 42 (2.0%) required further evaluation but the findings were not cancer
• 31 (1.5%) had lung cancer
There was also a variety of incidental findings, such as emphysema, other pulmonary abnormalities, and coronary artery calcification, noted on the scans of 857 patients (40.7%).
The researchers concluded that nearly 900,000 of a population of 6.7 million VHA patients met the criteria for LCS. Implementation of LCS in the VHA will likely lead to large numbers of patients eligible for LCS and will require substantial clinical effort for both patients and staff.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.